|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.40 USD | +1.38% |
|
-2.16% | +6.07% |
| Capitalization | 8.28B 7.06B 6.54B 6.15B 11.45B 754B 12.28B 75.5B 29.83B 358B 31.06B 30.42B 1,308B | P/E ratio 2025 * |
12.9x | P/E ratio 2026 * | 9.25x |
|---|---|---|---|---|---|
| Enterprise value | 9.01B 7.68B 7.11B 6.69B 12.45B 820B 13.36B 82.1B 32.43B 390B 33.77B 33.08B 1,422B | EV / Sales 2025 * |
6.71x | EV / Sales 2026 * | 4.75x |
| Free-Float |
98.92% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Halozyme Therapeutics, Inc.
| 1 day | +1.41% | ||
| 1 week | -2.16% | ||
| Current month | +6.07% | ||
| 1 month | +4.73% | ||
| 3 months | +6.74% | ||
| 6 months | +27.66% | ||
| Current year | +6.07% |
| 1 week | 69.53 |  | 73.76 |
| 1 month | 66.36 | | 75.59 |
| Current year | 67.16 | | 75.59 |
| 1 year | 47.5 | | 79.5 |
| 3 years | 29.85 | | 79.5 |
| 5 years | 29.85 | | 79.5 |
| 10 years | 6.96 | | 79.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 63 | 05/01/2014 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 43 | 01/02/2022 |
Charles Theuer
CTO | Chief Tech/Sci/R&D Officer | 62 | 30/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 58 | 27/03/2013 |
Helen Torley
BRD | Director/Board Member | 63 | 05/01/2014 |
| Chairman | 62 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.38% | -2.16% | +27.61% | +38.83% | 8.28B | |
| -0.60% | -1.65% | -13.44% | -35.18% | 64.05B | |
| +0.23% | +1.35% | +13.03% | -9.21% | 8.58B | |
| -4.36% | -6.86% | +4.88% | +59.00% | 6.32B | |
| -4.28% | -7.72% | -21.65% | +102.13% | 5.43B | |
| -0.20% | -2.82% | +167.21% | +37.60% | 4.11B | |
| +1.01% | -4.43% | -12.69% | -20.57% | 2.92B | |
| +0.38% | -3.26% | +29.89% | +21.69% | 2.86B | |
| +1.65% | +10.59% | +62.13% | +51.32% | 2.88B | |
| Average | -0.53% | -1.56% | +28.55% | +27.29% | 11.71B | |
| Weighted average by Cap. | -0.67% | -2.17% | +2.92% | -7.39% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.34B 1.14B 1.06B 997M 1.85B 122B 1.99B 12.23B 4.83B 58.07B 5.03B 4.93B 212B | 1.69B 1.44B 1.33B 1.25B 2.33B 154B 2.5B 15.39B 6.08B 73.05B 6.33B 6.2B 267B |
| Net income | 668M 570M 528M 496M 924M 60.81B 991M 6.09B 2.41B 28.92B 2.51B 2.45B 106B | 921M 785M 727M 684M 1.27B 83.8B 1.37B 8.39B 3.32B 39.85B 3.45B 3.38B 145B |
| Net Debt | 724M 617M 572M 538M 1B 65.88B 1.07B 6.6B 2.61B 31.33B 2.71B 2.66B 114B | -267M -228M -211M -198M -369M -24.3B -396M -2.43B -961M -11.55B -1B -981M -42.16B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/01/26 | 71.53 $ | +1.56% | 154,911 |
| 20/01/26 | 70.43 $ | -1.10% | 916,327 |
| 16/01/26 | 71.21 $ | -0.85% | 1,271,582 |
| 15/01/26 | 71.82 $ | -1.56% | 2,172,643 |
| 14/01/26 | 72.96 $ | +1.80% | 1,342,811 |
Delayed Quote Nasdaq, January 21, 2026 at 03:46 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition